Braizon Therapeutics, Inc. was established with the aim of applying and implementing, within the fields of medicine and life science, innovative technology for the delivery of drugs to the brain as the outcome of collaborative research by Professor Kazunori Kataoka from the Graduate School of Engineering/Medicine, the University of Tokyo and Professor Takanori Yokota from the Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University.
Professor Kataoka and Professor Yokota have codeveloped breakthrough technology enabling drug delivery across the blood-brain barrier (BBB) in close combination with nano-material engineering and neuroscience expertise, respectively.
Braizon Therapeutics has built a Drug Delivery System Platform from this technology, which we make available to Pharmaceutical, Biotechnology, and Academic partners globally through licensing partnerships. Building on the power of this platform technology and the drug development expertise with Team Braizon, we are creating new therapies for underserved CNS disorders within our ‘Needs-focused’ pipeline.
Braizon Therapeutics Board of Directors has extensive experience building, managing, and leading pharmaceutical businesses worldwide with a passion for translating nascent technologies into products with major positive social impact.
The leadership team comes from a diverse range of backgrounds to support the core focus of growing a stong CNS-focused Therapeutic company with leadership, financial, collaborative, drug development, and clinical translation skills.
As a science-founded and venture backed company focused on patient needs, Braizon Therapeutics is driven to enable better therapies for CNS disorders with our innovative drug delivery platform. Our drug delivery platform offers the highest level of drug delivery, powerful targeting, and exceptional versatility for the development of life-saving new therapies in the CNS. We generate value for our shareholders via licensing of this platform to pharmaceutical industry partners and incorporating the strengths into our in-house asset development.